Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000153139 | SCV000202600 | uncertain significance | not provided | 2014-02-17 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002516075 | SCV003487975 | pathogenic | Maple syrup urine disease | 2024-02-08 | criteria provided, single submitter | clinical testing | This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 122 of the DBT protein (p.Tyr122Cys). This variant is present in population databases (rs727503896, gnomAD 0.01%). This missense change has been observed in individual(s) with maple syrup urine disease (PMID: 34069211; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 166984). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on DBT protein function. For these reasons, this variant has been classified as Pathogenic. |
Revvity Omics, |
RCV002516075 | SCV003834263 | uncertain significance | Maple syrup urine disease | 2020-12-03 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV004567174 | SCV005059344 | likely pathogenic | Maple syrup urine disease type 1A | 2024-03-23 | criteria provided, single submitter | clinical testing |